Clinical overview: issues in Kaposi's sarcoma therapeutics.
Four questions are posed that are critical to the development of improved therapeutic and prophylactic strategies for Kaposi's sarcoma (KS). 1) Can we predict who will develop KS? Accurate identification of high-risk factors for KS development is essential for the development of KS prophylaxis trials. 2) Can developing insights into KS pathogenesis be translated into improved therapeutic and/or new prophylactic strategies for patients at high risk? Several approaches are being developed that target new blood vessel development, inflammatory cytokines, and the viruses that are implicated in KS pathogenesis. 3) How does the improved prognosis for human immunodeficiency virus (HIV)-infected patients affect KS treatment strategy? Improved anti-HIV therapy has implications for the timing of KS therapy, the choice of therapeutic approaches, and the potential for adverse drug interactions. 4) How can we best evaluate benefits from KS treatment? More rigorous, standardized criteria are in development and will be essential not only for accurate documentation of objective tumor regression, but also for assessment of tumor-associated symptom relief in a quantitative, function-oriented way.
Krown
S E
SE
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
D006678:HIV; D015658:HIV Infections / Q000188:drug therapy; D006801:Humans; D011379:Prognosis; D012514:Sarcoma, Kaposi / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control*